Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: A cost-effectiveness analysis

Journal of Evaluation in Clinical Practice

Volumn 16, Issue 4, 2010, Pages 744-755

  McIntyre, Roger S ^a   Cragin, Lael ^b   Sorensen, Sonja ^b   Naci, Huseyin ^b   Baker, Tim ^b   Roussy, Jean Pascal ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c PFIZER INC   (United States)

Author keywords

antipsychotic; Canada; cost effectiveness; schizophrenia; ziprasidone

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AKATHISIA; ANGINA PECTORIS; ARTICLE; BODY WEIGHT; CANADA; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG COST; DRUG EFFECT; FEMALE; HEALTH CARE COST; HEART INFARCTION; HOSPITALIZATION COST; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARKINSONISM; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RELAPSE; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SIDE EFFECT; STROKE; TARDIVE DYSKINESIA; WEIGHT CHANGE;

ADULT; ANTIPSYCHOTIC AGENTS; CANADA; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LONG-TERM CARE; MALE; MARKOV CHAINS; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 77954648452     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2009.01189.x     Document Type: Article

References (62)

1. WHO (2008) Schizophrenia Fact Sheet. Available at: http://www.who.int/ mental-health/media/en/55.pdf (last accessed 12 June 2009).
2. Government of Canada (2006) The Human Face of Mental Health and Mental Illness in Canada.
3. Goeree, R., Farahati, F., Burke, N., Blackhouse, G., O'Reilly, D., Pyne, J. Tarride, J. E. (2005) The economic burden of schizophrenia in Canada in 2004. Current Medicine Research Opinions, 21 (12 2017 2028.
4. American Psychiatric Association (2007) Available at: http://www.psych.org/ (last accessed 12 June 2009).
5. Lindstrom, E. B. K. (2000) Patient compliance with drug therapy in schizaophrenia. Pharmacoeconomics, 18, 106 124.
6. Rice, D. (1990) The economic impact of schizophrenia. Journal of Clinical Psychiatry, 60 (Suppl. 1 4 6.
7. Cohn, T., Prud'homme, D., Streiner, D., Kameh, H. Remington, G. (2004) Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Canadian Journal of Psychiatry, 49 (11 753 760.
8. el-Guebaly, N. Hodgins, D. C. (1992) Schizophrenia and substance abuse: prevalence issues. Canadian Journal of Psychiatry, 37 (10 704 710.
9. Coodin, S. (2001) Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry, 46 (6 549 555.
10. Goff, D. C., Sullivan, L. M., McEvoy, J. P., et al. (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research, 80 (1 45 53.
11. McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., Meltzer, H. Y., Hsiao, J., Scott Stroup, T. Lieberman, J. A. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80 (1 19 32.
12. Nasrallah, H. A. Newcomer, J. W. (2004) Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. Journal of Clinical Psychopharmacology, 24 (5 Suppl. 1 S7 S14.
13. Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L. S., Kreyenbuhl, J., Revicki, D. Buchanan, R. W. (2002) An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Archives of General Psychiatry, 59 (11 1021 1026.
14. Canadian Psychiatric Association (2005) Clinical practice guidelines: treatment of schizophrenia. Canadian Journal of Psychiatry, 50 (Suppl. 1 1 56.
15. Curkendall, S. M., Mo, J., Glasser, D. B., Rose Stang, M. Jones, J. K. (2004) Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. Journal of Clinical Psychiatry, 65 (5 715 720.
16. Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S. S., Magder, L. S., Kreyenbuhl, J., Revicki, D. A. Buchanan, R. W. (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. British Medical Journal, 325 (7358 243
17. Meyer, J. Koro, C. (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research, 70 (1 1 17.
18. Tandon, R. Jibson, M. (2003) Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology, 28 (Suppl. 1 9 26.
19. Pfizer Canada Inc 2008) Zeldox product monograph.
20. Daniel, D. G., Zimbroff, D. L., Potkin, S. G., Reeves, K. R., Harrigan, E. P. Lakshminarayanan, M. (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology, 20 (5 491 505.
21. Keck, P. Jr., Buffenstein, A., Ferguson, J., Feighner, J., Jaffe, W., Harrigan, E. P. Morrissey, M. R. (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl), 140 (2 173 184.
22. Keck, P. E. Jr., Reeves, K. R. Harrigan, E. P. (2001) Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies. Journal of Clinical Psychopharmacology, 21 (1 27 35.
23. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353 (12 1209 1223.
24. Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C. Weiden, P. J. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. The American Journal of Psychiatry, 156 (11 1686 1696.
25. Addington, D., Pantelis, C., Dineen, M., Benattia, I., Romano, S. J. Murray, S. (2003) Ziprasidone versus risperidone in schizophrenia: 52 weeks' comparative data. European Psychopharmacology, 13 (Suppl. 4 S299.
26. Simpson, G. M., Weiden, P., Pigott, T., Murray, S., Siu, C. O. Romano, S. J. (2005) Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. The American Journal of Psychiatry, 162 (8 1535 1538.
27. Simpson, G. M., Glick, I. D., Weiden, P. J., Romano, S. J. Siu, C. O. (2004) Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. The American Journal of Psychiatry, 161 (10 1837 1847.
28. Breier, A., Berg, P. H., Thakore, J. H., Naber, D., Gattaz, W. F., Cavazzoni, P., Walker, D. J., Roychowdhury, S. M. Kane, J. M. (2005) Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. The American Journal of Psychiatry, 162 (10 1879 1887.
29. Harvey, P. D., Siu, C. O. Romano, S. (2004) Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl), 172 (3 324 332. (Pubitemid 38392326)
30. Kinon, B. J., Lipkovich, I., Edwards, S. B., Adams, D. H., Ascher-Svanum, H. Siris, S. G. (2006) A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. Journal of Clinical Psychopharmacology, 26 (2 157 162.
31. Chan, M. P. Conacher, G. N. (1994) Legally untreatable - a new category of long stay patient? Canadian Journal of Psychiatry, 39 (7 433 435.
32. Colditz, G. A., Willett, W. C., Stampfer, M. J., Manson, J. E., Hennekens, C. H., Arky, R. A. Speizer, F. E. (1990) Weight as a risk factor for clinical diabetes in women. The American Journal of Epidemiology, 132 (3 501 513.
33. Anderson, K. M., Odell, P. M., Wilson, P. W. Kannel, W. B. (1991) Cardiovascular disease risk profiles. American Heart Journal, 121 (1 Pt 2 293 298.
34. D'Agostino, R. B., Russell, M. W., Huse, D. M., Ellison, R. C., Silbershatz, H., Wilson, P. W. Hartz, S. C. (2000) Primary and subsequent coronary risk appraisal: new results from the Framingham Study. American Heart Journal, 139 (2 Pt 1 272 281.
35. Wolf, P. A., D'Agostino, R. B., Belanger, A. J. Kannel, W. B. (1991) Probability of stroke: a risk profile from the Framingham Study. Stroke, 22 (3 312 318.
36. Stevens, R. J., Kothari, V., Adler, A. I. Stratton, I. M. (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clinical Science (Lond), 101 (6 671 679.
37. Kothari, V., Stevens, R. J., Adler, A. I., Stratton, I. M., Manley, S. E., Neil, H. A. Holman, R. R. (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke, 33 (7 1776 1781.
38. Brown, S. (1997) Excess mortality of schizophrenia: a meta-analysis. The British Journal of Psychiatry, 171, 502 508.
39. RAMQ (2008) Régie d'assurance maladie du Québec (RAMQ) Drug Formulary.
40. Ontario Ministry of Health and Long-Term Care (2005) Ontario Drug Benefit Formulary/Comparative Drug Index.
41. O'Brien, J. A., Patrick, A. R. Caro, J. J. (2003) Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Services Research, 3 (1 7.
42. Ontario Cost Casing initiative (OCCI) 2005) Ontario Case Costing Initiative. Available at: http://www.occp.com/ (last accessed 7 February 2007).
43. Radensky, P. W., Berliner, E., Archer, J. W. Dournaux, S. F. (2001) Inpatient costs of major cardiovascular events. The American Journal of Cardiovascular Drugs, 1 (3 205 217.
44. Ontario Ministry of Health and Long-Term Care (2007) Schedule of Benefits - Physician Services Under the Health Insurance Act.
45. Simpson, S. H., Corabian, P., Jacobs, P. Johnson, J. A. (2003) The cost of major comorbidity in people with diabetes mellitus. CMAJ: Canadian Medical Association Journal, 168 (13 1661 1667.
46. Kopala, L., Smith, G., Malla, A., Williams, R., Love, L., Talling, D. Balshaw, R. (2006) Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders. Acta Psychiatrica Scandinavian Supplementum, 430, 29 39.
47. Tousignant, M., Hebert, R., Desrosiers, J. Hollander, M. J. (2003) Economic evaluation of a geriatric day hospital: cost-benefit analysis based on functional autonomy changes. Age Ageing, 32 (1 53 59.
48. Reid, R., Fodor, G., Lydon-Hassen, K., D'Angelo, M. S., McCrea, J., Bowlby, M. Difrancesco, L. (2002) Dietary counselling for dyslipidemia in primary care: results of a randomized trial. Canadian Journal of Dietetic Practice and Research, 63 (4 169 175.
49. Vera-Llonch, M., Delea, T. E., Richardson, E., Rupnow, M., Grogg, A. Oster, G. (2004) Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health, 7 (5 569 584.
50. Poulin, M. J., Cortese, L., Williams, R., Wine, N. McIntyre, R. S. (2005) Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Canadian Journal of Psychiatry, 50 (9 555 562.
51. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists & North American Association for the Study of Obesity 2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27 (2 596 601.
52. Bernardo, M., Ramon Azanza, J., Rubio-Terres, C. Rejas, J. (2006) Cost-effectiveness analysis of schizophrenia relapse prevention: an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain. Clinical Drug Investigation, 26 (8 447 457.
53. Volz, H.-P., Sadre-Chirazi-Stark, M. Resch, A. (2005) Cost-effectiveness of treating schizophrenia with ziprasidone versus other antipsychotics considering adverse drug reactions and non-compliance. Gesundheitsokonomie und Qualitatsmanagement, 10 (2 96 101.
54. Rosenheck, R. A., Leslie, D. L., Sindelar, J., et al. (2006) Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American Journal of Psychiatry, 163 (12 2080 2089.
55. Statistique Canada 2007) Census of Canada 2001. Available at: http://www12.statcan.ca/english/census01/home/Index.cfm (last accessed 2 February 2007).
56. The Society of Obstetricians and Gynaecologists of Canada (2006) The Journalist's Menopause Handbook.
57. Daniel, D. G. (2003) Tolerability of ziprasidone: an expanding perspective. Journal of Clinical Psychiatry, 64 (Suppl. 19 40 49.
58. Revicki, D. A., Shakespeare, A. Kind, P. (1996) Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. International Clinical Psychopharmacology, 11 (2 101 108.
59. Lenert, L. A., Sturley, A. P., Rapaport, M. H., Chavez, S., Mohr, P. E. Rupnow, M. (2004) Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophrenia Research, 71 (1 155 165.
60. Schultz, S. E. Kopec, J. A. (2003) Impact of chronic conditions. Health Report, 14 (4 41 53.
61. Trakas, K., Oh, P. I., Singh, S., Risebrough, N. Shear, N. H. (2001) The health status of obese individuals in Canada. International Journal of Obesity and Related Metabolic Disorders, 25 (5 662 668.
62. Mittmann, N., Trakas, K., Risebrough, N. Liu, B. A. (1999) Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics, 15 (4 369 376.